Payment overview · 2025
General Payments
$632.61
15 reported records · 10 companies
Healthcare provider profile · identity verified
Farnoush Karimpour, FNP-BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · VISALIA, CA · NPI 1902248859
Verified facts
What the public records show
CMS Open Payments records show Farnoush Karimpour, FNP-BC received $632.61 in general payments during 2025 across 15 reported records.
Lilly USA, LLC accounted for 41.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $264.17 | 41.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $110.71 | 17.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $103.50 | 16.4% | 2 | 2025 |
| LEO Pharma Inc. | Unresolved — no canonical attribution shown | $39.79 | 6.3% | 2 | 2025 |
| Virtus Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $25.97 | 4.1% | 1 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $23.06 | 3.6% | 1 | 2025 |
| Biofrontera Inc. | Unresolved — no canonical attribution shown | $18.31 | 2.9% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $17.99 | 2.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.88 | 2.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.23 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $632.61 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $133.57 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $130.60 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $110.71 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $103.50 | 2 | 2025 |
Source payment records
|
|||||
| ANZUPGO Normalized: anzupgo |
Drug | LEO Pharma Inc. | $39.79 | 2 | 2025 |
Source payment records
|
|||||
| LEVORPHANOL TARTRATE Normalized: levorphanol tartrate |
Drug | Virtus Pharmaceuticals LLC | $25.97 | 1 | 2025 |
Source payment records
|
|||||
| SIMPLIMAX Normalized: simplimax |
Medical Supply | Organogenesis Inc. | $23.06 | 1 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
91 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
132 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
103 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
105 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 359 | 96 |
| Metformin Hcl | Metformin Hcl | 294 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 223 | 63 |
| Lisinopril | Lisinopril | 222 | 63 |
| Gabapentin | Gabapentin | 188 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 186 | 50 |
| Omeprazole | Omeprazole | 177 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 169 | 49 |
| Famotidine | Famotidine | 150 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 150 | 49 |
| Simvastatin | Simvastatin | 143 | 42 |
| Jardiance | Empagliflozin | 132 | 25 |
| Losartan Potassium | Losartan Potassium | 123 | 33 |
| Alendronate Sodium | Alendronate Sodium | 110 | 28 |
| Rybelsus | Semaglutide | 105 | 24 |
| Montelukast Sodium | Montelukast Sodium | 104 | 27 |
| Ozempic | Semaglutide | 103 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 100 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 98 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 91 | 19 |
| Celecoxib | Celecoxib | 89 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 83 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 80 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 25 |
| Glipizide Er | Glipizide | 77 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 20 |
| Allopurinol | Allopurinol | 59 | 15 |
| Carvedilol | Carvedilol | 52 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 16 |
| Lovastatin | Lovastatin | 49 | 13 |
| Sertraline Hcl | Sertraline Hcl | 46 | 16 |
| Ibuprofen | Ibuprofen | 45 | 26 |
| Linzess | Linaclotide | 42 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 11 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 42 | suppressed |
| Trulicity | Dulaglutide | 42 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 40 | 12 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 40 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | 11 |
| Naproxen | Naproxen | 35 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Glipizide | Glipizide | 34 | 12 |
| Furosemide | Furosemide | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Meloxicam | Meloxicam | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Eliquis | Apixaban | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 21 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Rifampin | Rifampin | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $632.61 · 15 records | Lilly USA, LLC | AIRSUPRA, ANZUPGO, Bimzelx, CAPVAXIVE, ENFLONSIA, GARDASIL 9, LEVORPHANOL TARTRATE, MOUNJARO, ROTATEQ, SHINGRIX, SIMPLIMAX, VAXNEUVANCE, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error